Tutorial
Robinhood Chain
…
Wallet
Overview
Follow the Money
Daily Brief
Live
Congress
Directory
Corporate Insiders
Planned Sales & Stakes
Government Money
Political Influence
Institutions
Washington Network
Follow the Power
Disclosure Clock
AI Investigator
Watchlist
Convergence
INSIDER Alpha
Signal ledger
Historical Replay
Robinhood Chain
Proof
Trading
Token
Pro
Account
Methodology
Tutorial
Profile · INSIDER
Overview
Follow the Money
Daily Brief
Live
Congress
Directory
Corporate Insiders
Planned Sales & Stakes
Government Money
Political Influence
Institutions
Washington Network
Follow the Power
Disclosure Clock
AI Investigator
Watchlist
Convergence
INSIDER Alpha
Signal ledger
Historical Replay
Robinhood Chain
Proof
Trading
Token
Pro
Account
Methodology
Overview
Follow the Money
Daily Brief
Live
Congress
Directory
Corporate Insiders
Planned Sales & Stakes
Government Money
Political Influence
Institutions
Washington Network
Follow the Power
Disclosure Clock
AI Investigator
Watchlist
Convergence
INSIDER Alpha
Signal ledger
Historical Replay
Robinhood Chain
Proof
Trading
Token
Pro
Account
Methodology
Tutorial
Data sources
SEC Form 4
2h ago
House PTR
2h ago
SEC 13F
2h ago
Robinhood Chain
2h ago
Public company
Silence Therapeutics plc
SLN
CIK 0001479615
EDGAR filings
Open in network
○
Watch SLN
Price
$19.73
1 year
+216.2%
Disclosed transactions
2
Buys / sells
0 / 0
Max Insider Score
9
Connections with evidence
3
Customize layout
SLN · disclosed activity on price
Disclosed transactions
Score
Actor
Security
Side
Value
Executed
Disclosed
Lag
Source
Evidence
9
EJ
Ede-Golightly James
Director
SLN
Silence Therapeutics plc
Grant or award
A
—
90.0K sh
Jan 2, 2026
Jan 6, 2026
Verified connections
In industry
evidence
Pharmaceuticals, devices & health services
SEC SIC 2834 · Pharmaceutical Preparations · Nov 5, 2026
← Holds over 5% of
evidence
FMR LLC
7.1% of class · Schedule 13G · Nov 4, 2026
← Insider of
evidence
Ede-Golightly James
Director · Dec 22, 2025
traded Jan 2, 2026
+4d
SEC Form 4
Evidence
Evidence
Close
9
EJ
Ede-Golightly James
Director
SLN
Silence Therapeutics plc
Grant or award
A
—
90.0K sh
Dec 22, 2025
Dec 22, 2025
traded Dec 22, 2025
+0d
SEC Form 4
Evidence
Evidence
Close
Planned sales and 5% stakes
Form 144, 13D and 13G
FM
FMR LLC
Passive holder · crossed on Sep 30, 2026 · 13.18M shares
7.1% of class
13G · filed Nov 5, 2026
Disclosed trades
TradingView